USAEUROPEViVE
ABOUTSPONSORSHIPFOUNDATION
Logo Hlth
Logo Hlth
18 Jan 2023 | 03:45 PM GMT

Digital Health for Trigger Management in Autoimmune Conditions

Anchored by:

Melinda Decker
Advisor
PLEXUS VENTURES

Participants:

Melinda Decker AdvisorPlexus Ventures
Melinda Decker
AdvisorPlexus Ventures
Chandana Fitzgerald President, CommunityHLTH
Chandana Fitzgerald
President, CommunityHLTH
Amanda Woodward Insights ManagerTwill
Amanda Woodward
Insights ManagerTwill
Anuj Patel CEO & FounderMotto
Anuj Patel
CEO & FounderMotto
Bill Snyder CEOCylinder
Bill Snyder
CEOCylinder
Cathy Zaremba Director, Product MarketingBrightInsight
Cathy Zaremba
Director, Product MarketingBrightInsight
Marc Blanchard Founder & CEOATREON
Marc Blanchard
Founder & CEOATREON
Marcus Bates VP Business DevelopmentAptar Digital Health
Marcus Bates
VP Business DevelopmentAptar Digital Health
Mette Dyhrberg Founder & CEOMymee
Mette Dyhrberg
Founder & CEOMymee
Nader Alaghband Co-Founder & CEOAmpersand Health
Nader Alaghband
Co-Founder & CEOAmpersand Health
Susan Bratton CEOSavor Health
Susan Bratton
CEOSavor Health
Wen Dombrowski MD MBA Chief Convergence OfficerCATALAIZE
Wen Dombrowski MD MBA
Chief Convergence OfficerCATALAIZE

About this Meeting

It can be hard for HCPs to provide precise medical decisions in autoimmune conditions due to the patient variability and the trigger events not being fully understood. That is exactly where digital health tools can come into play, to ultimately create a better view of the patient’s condition and thereby enable better treatment and management, hence a more holistic approach.  

How can we use digital health tools to track the triggers in autoimmune conditions? Join us on this interesting session where we will talk about:   

  • A stabilized patient with an autoimmune condition might have an event that triggers disease symptoms (e.g stress, fatigue, chronic pain, etc.). Identifying these events may be challenging due to patient variability. How can we use digital health to pin down the triggers?  
  • Once identified, how can we use digital health for a personalized approach that helps prevent those triggers?  
  • What measures can these digital health companies use to prove better patient outcomes and cost reduction?   
  • Considering the cost burden of autoimmune disease, payers seem to be a key stakeholder these companies can engage with. How can payers benefit from these solutions? How can digital health companies convince  them of the real value in managing triggers in autoimmune conditions? 
  • What is the role of pharma in preventing those triggers? What is the benefit for them in pairing their drugs with these digital solutions?

We would like to remind you that our meetings are small and intimate sessions with a limited number of seats available, therefore we rely on your attendance and participation to ensure a high quality and valuable meeting for all. If you are confirmed for this meeting we ask if you can please ensure your attendance on the day.